Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis

NCT00464204 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Sepsis

Interventions

DRUG: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"
DRUG: 0.9 % NaCl

Sponsor

Fresenius Kabi